Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis

In this trial, patients with secondary hyperparathyroidism who were undergoing dialysis were assigned to receive either the calcimimetic agent cinacalcet or placebo. Cinacalcet did not significantly reduce the risk of death or major cardiovascular events. Cardiovascular disease is very common among...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2012-12, Vol.367 (26), p.2482-2494
Hauptverfasser:	Chertow, Glenn M, Block, Geoffrey A, Correa-Rotter, Ricardo, Drüeke, Tilman B, Floege, Jürgen, Goodman, William G, Herzog, Charles A, Kubo, Yumi, London, Gerard M, Mahaffey, Kenneth W, Mix, T Christian H, Moe, Sharon M, Trotman, Marie-Louise, Wheeler, David C, Parfrey, Patrick S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Biological and medical sciences Cardiovascular Diseases - etiology Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cinacalcet Female General aspects Humans Hyperparathyroidism, Secondary - drug therapy Hyperparathyroidism, Secondary - etiology Hypocalcemia - chemically induced Intention to Treat Analysis Kidney Failure, Chronic - complications Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - therapy Male Medical sciences Middle Aged Naphthalenes - adverse effects Naphthalenes - therapeutic use Odds Ratio Parathyroid Hormone - blood Renal Dialysis - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!